Original Article

4-Methylthio-3-butenyl isothiocyanate (raphasatin) exerts chemopreventive effects against esophageal carcinogenesis in rats

Isamu Suzuki1, 2, Young-Man Cho1*, Tadashi Hirata1, 3, Takeshi Toyoda1, Jun-ichi Akagi1, Yasushi Nakamura4, 5, Eun Young Park4, 6#, Azusa Sasaki4, Takako Nakamura4, Shigehisa Okamoto7, Koji Shirotanoboru, Noboru Sue1me5, Akiyoshi Nishikawa2, 8, and Kumiko Ogawa1

1 Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
2 Pathogenetic Veterinary Science, United Graduate School of Veterinary Sciences, Gifu University, 1-1 Yanagido, Gifu, Gifu 501-1193, Japan
3 Department of Pharmacology, School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
4 Faculty of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Shimogamogahangi-cho, Sakyo-ku, Kyoto 606-8522, Japan
5 Kyoto Prefectural Agriculture, Forestry & Fisheries Technology Center, 9 Wakunari, Amakusa, Kameoka, Kyoto 621-0806, Japan
6 Department of Food Science, Korea Christian University, Kkachisan-ro 24-gil, Gangseo-gu 47, Seoul 07661, Republic of Korea
7 Department of Food Science and Biotechnology, Kagoshima University, 1-21-24 Korimoto, Kagoshima, Kagoshima 890-0065, Japan
8 Biological Safety Research Center, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

Abstract: To examine the effects of 4-methylthio-3-butenyl isothiocyanate on esophageal carcinogenesis, male 6-week-old F344 rats were subcutaneously injected with 0.5 mg/kg body weight N-nitrosomethylbenzylamine three times per week for 5 weeks and fed a diet supplemented with 80 ppm 4-methylthio-3-butenyl isothiocyanate, equivalent to 6.05 mg/kg body weight/day for the initiation stage, 4.03 mg/kg body weight/day for the promotion stage, or 4.79 mg/kg body weight/day for all stages. Although the incidence of lesions was not affected by 4-methylthio-3-butenyl isothiocyanate treatment, the multiplicity of squamous cell papilloma in the esophagus was significantly decreased in rats in the 4-methylthio-3-butenyl isothiocyanate initiation stage group (1.13 ± 0.74), 4-methylthio-3-butenyl isothiocyanate promotion stage group (1.47 ± 0.99), and 4-methylthio-3-butenyl isothiocyanate all stage group (1.47 ± 1.13) as compared with rats treated with N-nitrosomethylbenzylamine alone (3.00 ± 1.46). Immunohistochemical analysis revealed that 4-methylthio-3-butenyl isothiocyanate induced apoptosis, suppressed cell proliferation, and increased p21 expression when administered in the promotion phase. These modifying effects were not observed in the rats treated with 4-methylthio-3-butenyl isothiocyanate alone. Our results indicated that 4-methylthio-3-butenyl isothiocyanate may exert chemopreventive effects against N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. (DOI: 10.1293/tox.2016-0037; J Toxicol Pathol 2016; 29: 237–246)

Key words: 4-methylthio-3-butenyl isothiocyanate, raphasatin, esophageal cancer, N-nitrosomethylbenzylamine, chemoprevention

Introduction

Esophageal cancer is the tenth most common cancer and the sixth most common cause of cancer-related deaths worldwide (about 400,000 deaths/year)1. In addition, it is one of the most lethal malignancies, with a 5-year survival rate of only 17% in the USA from 1996 to 20042, 3. In Japan, the 10-year relative survival rate of men with esophageal cancer was reported to be 24.0%; this was lower than that of other digestive tract cancers (gastric cancer, 61.3%; colon cancer, 68.9%) from 2002 to 20064. Therefore, effective chemopreventive approaches against this disease are urgently required.

Esophageal squamous cell carcinoma (ESCC) is one of the most predominant histological types of esophageal cancer. Epidemiological studies have shown that tobacco smoking, excessive alcohol consumption, and eating pickled vegetables are associated with increased risk of ESCC; these habits can lead to the endogenous generation of nitrosamines, a common type of carcinogen5. Furthermore, high concentrations of nitrate nitrogen, the precursor of nitrosamine, in drinking water can increase the risk of ESCC6. In contrast, the consumption of fruits and vegetables has been
shown to be associated with a reduced risk of ESCC\(^7,8\). In these population-based prospective cohort studies, researchers found a dose-dependent decrease in the risk of ESCC associated with a higher intake of total fruits and vegetables. Of the five fruit and vegetable subgroups investigated in the study of Yamaji et al., only individuals consuming cruciferous vegetables had a significantly reduced risk of ESCC on further adjustment for smoking and alcohol consumption status\(^8\). Among the different types of fruits and vegetables, cruciferous vegetables may provide a good source of effective cancer-preventing compounds\(^8\). In particular, isothiocyanates (ITCs), one of the constituents in cruciferous vegetables, have been extensively investigated and have attracted considerable attention owing to their promising chemopreventive effects\(^9\).

ITCs have been shown to suppress tumor development in rodent carcinogenesis models of various organs\(^9–11\). Moreover, phenethyl isothiocyanate (PEITC) has been reported to suppress N-nitrosomethylbenzylamine (NMBA)-induced rat esophageal carcinogenesis when rats are treated throughout the experiment\(^12–14\). 4-Methylthio-3-butenyl isothiocyanate (MTBITC), a component of the daikon (Japanese white radish), was also found to have antimutagenic effects in an in vitro study\(^15\) and was shown to suppress pancreatic carcinogenesis in hamsters treated with \(N\)-nitrosos(2-oxopropyl)amine (BOP) when given during the initiation stage\(^16\). MTBITC is a pungent component of the roots of crucifers, such as daikon; therefore, heirloom types of daikon (e.g., Karami, Momoyama, and Sabaga), which are more pungent than the conventional type of daikon (Aokubi), are a rich source of MTBITC\(^17\). Although several in vitro studies have shown that MTBITC has chemopreventive properties, such as anti-proliferative and pro-apoptotic effects\(^20–22\), few reports have assessed the chemopreventive effects of this compound in vivo\(^23\), and it is unclear whether MTBITC exerts chemopreventive effects in esophageal carcinogenesis.

In this study, we aimed to clarify the potential chemopreventive effects of MTBITC in an in vivo model of esophageal carcinogenesis. For this purpose, we employed an NMBA-induced rat esophageal carcinogenesis model to allow the initiated cells to develop into preneoplastic/neoplastic lesions from squamous cells rapidly. NMBA is a carcino- genic nitrosamine that is found in the diet in regions of the world where individuals are at high risk of ESCC\(^24\). The NMBA-induced rat esophageal carcinogenesis model has been extensively used because the relatively short-term (5 weeks) NMBA-treatment protocol results in a 100% tumor incidence within 23 weeks after the first administration of NMBA and allows for evaluation of the effects of compounds administered before, during, and after NMBA treatment\(^14–16\). Using this model, we were able to assess the potential influence of MTBITC on the induction and subsequent progression of esophageal neoplasms. In addition, we performed immunohistochemical analysis to assess the mechanisms involved in MTBITC-dependent chemoprevention.

### Materials and Methods

#### Chemicals

MTBITC was extracted and purified from the roots of heirloom varieties of daikon (\(Raphanus sativus\)) in Kyoto (Momoyama and Sabaga) as previously described\(^19\) and then stored at \(-80^\circ\)C until use. The purity of the MTBITC was 98.0%, as estimated by high-performance liquid chromatography (HPLC; Shimadzu, Kyoto, Japan). NMBA (Nard, Osaka, Japan) was dissolved in 20% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) in saline and was administered at a volume of 5 mL/kg body weight (BW).

#### Experimental animals and housing conditions

A total of 95 four-week-old male F344/DuCrj rats were obtained from Charles River Laboratories Japan (Yokohama, Japan) and acclimatized for 1 week prior to testing. The rats were housed in polycarbonate cages (3–4 rats per cage) with softwood chips for bedding in a specific pathogen-free facility and maintained under controlled conditions (temperature, 23 ± 2°C; relative humidity, 55 ± 5%; air changes, 12 times/h; and lighting, 12-h light-dark cycle) with free access to the basal diet or test diet and tap water.

#### Experimental protocol

MTBITC was mixed into a powdered basal diet (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan) at 80 ppm based on its ability to suppress pancreatic tumors in the hamsters\(^18\). The stability of MTBITC in the mixed diet was analyzed by HPLC, and the concentrations of MTBITC in the mixed diet preserved at 4°C for 4 days and 1 week were 96.6% and 90.7%, respectively, whereas those in mixed diets stored at room temperature for 4 days and 1 week were 75.3% and 75.1%, respectively. The MTBITC/diet admixture was prepared once per week and kept at 4°C in a refrigerator, and the contents of the feeding jar were exchanged twice per week.

As shown in Fig. 1, groups 1 (untreated) and 2 (MTBITC-treated) included 10 rats (5 weeks old) each that were fed the basal diet or a diet containing 80 ppm MTBITC without NMBA treatment or DMSO (vehicle) for analysis of the effects of MTBITC alone. Rats in groups 3 (DMSO-treated; \(n = 15\)) and 4 (NMBA-treated; \(n = 15\)) were fed the basal diet throughout the experiment and treated with DMSO or NMBA, respectively. NMBA was administered subcutaneously 3 times per week for 5 weeks at a dose of 0.5 mg/kg BW as previously described\(^15\). Groups 5–7 (\(n = 15\) animals each) were given both NMBA and MTBITC as follows: for the initiation stage of treatment, from 1 week before NMBA treatment, rats were simultaneously given a diet mixed with 80 ppm MTBITC for 7 weeks and then the basal diet (group 5; NMBA+MTBITC/basal diet); for the promotion stage of treatment, starting 1 week after the end of NMBA treatment, the animals were continuously fed the MTBITC diet for 19
weeks (group 6; NMBA/MTBITC); finally, for all stages of treatment, the MTBITC diet was given throughout the experimental period (group 7; NMBA+MTBITC/MTBITC).

The animals were observed daily and weighed once per week during the experimental period. The amounts of supplied and residual diet were weighed twice per week, when the contents of the feeding jars were exchanged, in order to calculate the average daily food consumption and MTBITC intake throughout the treatment period. At experimental week 26, all animals were anesthetized with isoflurane (Mylan Inc., Tokyo, Japan), and blood samples were collected from the abdominal aorta for hematology and serum biochemistry in groups 1 and 2. Other animals were then euthanized by exsanguination from the abdominal aorta. The protocol was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences (Tokyo).

**Hematology and serum biochemistry**

To examine whether the dose of MTBITC used in this study itself exerts any effects in rats, hematology and serum biochemistry were analyzed in groups 1 and 2. Hematological examination was performed using a K-4500 automatic hematology analyzer (Sysmex Corp., Kobe, Japan). Aliquots of whole blood samples were mixed with 4 volumes of the supplier’s buffer containing 0.5% ethylenediaminetetraacetic acid (EDTA)·2K and applied to the analyzer for the following parameters: white blood cell count (WBC), red blood cell count (RBC), hemoglobin concentration (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT). To measure the differential leukocyte and reticulocyte counts, aliquots of whole blood samples were mixed with a one-fourth volume of 5.0% EDTA·2K solution. Blood smears were then processed for May-Grunwald Giemsa staining and analyzed with a Microx HEG-50S (Sysmex). Serum biochemistry was analyzed at SRL, Inc. (Tokyo, Japan), using sera frozen after centrifugation of whole blood (1,000 × g for 10 min). The following parameters were analyzed: total protein (TP), albumin (Alb), albumin/globulin ratio (A/G), total bilirubin (Bil), glucose, triglyceride (TG), total cholesterol (T-Ch), urea nitrogen (BUN), creatinine (Cre), sodium (Na), chloride (Cl), potassium (K), calcium (Ca), inorganic phosphorus (IP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (γ GTP).

**Organ weights and histopathological assessment**

After necropsy, the esophagus, tongue, and stomach were removed from all rats. In groups 1 and 2, the brain, thymus, lungs, heart, spleen, liver, adrenal glands, kidneys, and testes were weighed, and the skin, mammary glands, femur with marrow, sternum with marrow, mesenteric lymph nodes, salivary glands (sublingual and submandibular), aorta, trachea, small intestine (duodenum, jejunum, and ileum), large intestine (cecum, colon, and rectum), pancreas, urinary bladder, epididymides, seminal vesicles, prostate gland, pituitary gland, parathyroid glands, spinal cord with vertebrae (cervical, thoracic, and lumbar portions), trigeminal and sciatic nerves, eyes, Harderian glands, femoral skeletal muscle, and nasal cavity were removed to examine whether the dose of MTBITC used in this study itself exerts any effects in rats. To evaluate the chemopreventive effects of MTBITC, the esophagus of each rat was opened longitudinally, and surface nodules greater than 0.5 mm in a single dimension were mapped, counted, and measured. This size is used to ensure detection of proliferative lesions, and it was also applied in previous NMBA-induced esophageal carcinogenesis studies. The esophagus was unbent and fixed on a filter paper to make it flat. The organs were then fixed in 10% buffered formalin for 3 days. Tissues and eyes were fixed in Bouin’s solution and Davidson’s solution, respectively. The nasal cavity, vertebrae, sternum, and femur were treated with a mixture of 10% formic acid and 10% buffered formalin for up to 3 weeks for decalcification. After fixation, the entire length of the esophagus was cut into 2 or 3 sections including all nodules greater than 0.5 mm in diameter. Tissue slices of all organs were routinely processed for paraffin embedding, and sections were prepared and stained with hematoxylin and eosin (HE) for histopathological evaluation. Esophageal lesions were classified into hyperplasia, atypical hyperplasia (i.e., dysplasia), papilloma, and carcinoma of squamous cells based on histopathological features in rats, in accordance with the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND). Diagnostic features are as follows. Atypical hyperplasia reveals the thickening of squamous epithelium with the presence of abnormal cell shape, size,
or nuclear morphology, and keratinization of cells within deeper layers of mucosa is seen. Papilloma is characterized by branching central fibrovascular stalks that are covered by a variably thick and differentiated squamous epithelium that is often heavily keratinized. Cells comprising a carcinoma show features such as loss of polarity (for example, basal-like tumor cells suddenly forming keratin pearls), an abundance of mitotic figures, cellular and nuclear pleomorphism, and foci of necrosis.

Immunohistochemistry

Esophageal tissues were embedded in paraffin, sectioned to a thickness of 4-μm, and subjected to immunohistochemistry using a Vectastain Elite ABC Kit (Vector Laboratories Inc., Burlingame, CA, USA) or Histofine Simple Stain Kit (Nichirei Corp, Tokyo, Japan) with 3, 3′-diaminobenzidine/H₂O₂ as a chromogen. The following primary antibodies were used: anti-cleaved caspase-3 rabbit monoclonal antibodies (clone 5A1E, 1:500; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-Ki-67 rabbit monoclonal antibodies (clone SP6, 1:1,000; Abcam, Cambridge, CA, USA), anti-p21 rabbit monoclonal antibodies (clone EPR3993, 1:2,000; Abcam), and anti-p53 mouse monoclonal antibodies (clone PAb 240, 1:2,500; Abcam). Antigen retrieval was performed in an autoclave for 10 min at 121°C in 10 mM citrate buffer (pH 6.0) for Ki-67, p21, and p53 or in a microwave for 10 min at 90°C in Target Retrieval Solution, pH 9 (Dako, Tokyo, Japan), for cleaved caspase-3.

Immunohistochemical analysis was performed for rats in groups 2–7. All immunostained slides were counterstained with hematoxylin for microscopic examination. To compare the effects of MTBITC on early-stage esophageal carcinogenesis, we analyzed normal looking epithelia from rats in groups 2 and 3 or diffuse hyperplastic epithelia (i.e., the majority of the mucosa consisting of squamous cells in increased layers other than focal preneoplastic/neoplastic lesions in NMBA-treated animals) in groups 4–7. The numbers of positive cells were counted in 5 randomly selected areas per epithelium at a magnification of 200× from 10 randomly selected rats per group, and cell numbers were normalized to the unit length of the muscularis mucosae in accordance with Taniai et al.26.

Statistical analysis

All data were expressed as means ± SDs per group, and the data of groups 3 and 4 were compared with those of the other groups to evaluate the effects of MTBITC on NMBA-induced rat esophageal carcinogenesis. For comparison of numerical data between multiple groups, Bartlett’s test for equal variance was used to determine whether variances were homogenous between the groups. If a significant difference in variance was not observed, one-way analysis of variance (ANOVA) was performed. If significant differences were found, Dunnett’s multiple comparison tests (for multiplicity data) or Tukey-Kramer’s multiple range tests (for other data) were performed for comparisons between the groups. If a significant difference was found using Bartlett’s test, Kruskal-Wallis tests were performed. If significant differences were found, Steel tests (for multiplicity data) or Steel-Dwass tests (for other data) were applied.

The significance of differences in data for hematology, serum biochemistry, and organ weights (both absolute and relative weights) between groups 1 and 2 was analyzed with Student-Welch tests. For histopathological findings, Fisher’s exact probability tests were performed. Differences with P values of less than 0.05 were considered statistically significant.

Results

One rat in group 3 became emaciated due to malocclusion and was excluded from the study. No treatment-related clinical signs or deaths were detected during the 26-week study period. The treatments did not affect body weight. Analysis of food consumption revealed that rats in groups 2, 5, 6, and 7 consumed 4.64, 6.05, 4.03, and 4.79 mg MT-BITC/kg BW/day, respectively (Table 1).

No MTBITC-related changes were observed in hematological parameters, serum biochemistry, organ weights, and histopathological features in groups 1 and 2, except for incidental and spontaneous changes (data not shown). A significant low value for lung weight was observed in group 2, but it was thought to be incidental, since the difference was minimal and no significant histopathological change was observed.

The incidence and multiplicity data for macroscopic esophageal nodules greater than 0.5 mm in diameter in each group are summarized in Table 2. The nodules were diagnosed as squamous cell hyperplasia, atypical hyperplasia, papilloma, or carcinoma, as described later. No statistically significant differences in the incidence of nodules were detected among groups 4–7. In contrast, the multiplicities of nodules in groups 5–7 were significantly lower than that in group 4 (P<0.01).

The incidence and multiplicity data of esophageal pre-neoplastic/neoplastic lesions, as identified by histological assessment, are shown in Table 3, and the representative appearance of each lesion is shown in Fig. 2. There were no significant differences in the incidences of lesions among groups 4–7. However, the multiplicity data for atypical hyperplasia (P<0.05 in groups 5 and 7) and for papilloma (P<0.01 in groups 5–7) were significantly decreased compared with those in group 4. As for carcinoma, the animals in groups 6 and 7 revealed a tendency to exhibit slightly lower incidence and multiplicity data than those in group 4, without statistical significance. Moreover, focal hyperplasia and papilloma of squamous cells in the tongue was sporadically detected in rats in groups 4–7; however, there were no significant differences in the incidence and multiplicity data (data not shown). Additionally, no changes were observed in the stomach in all groups of rats.

The results of the immunohistochemical analysis are graphically summarized in Fig. 3. The numbers of epithelial cells positive for cleaved caspase-3, the activated form of
caspase-3 involved in apoptotic signaling, were significantly higher in groups 5–7 than in group 3 \((P<0.01)\). The animals in group 4 also showed a tendency to exhibit a higher number of positive cells than the animals in group 3; however, this difference was not statistically significant. Moreover, the numbers of positive cells in groups 6 and 7 were significantly increased as compared with those in group 4 \((P<0.05)\).

We next examined cell proliferation by analysis of Ki-67, an established cell proliferation marker. The numbers of Ki-67-positive cells in groups 4 and 5 were significantly increased as compared with that in group 3 \((P<0.01)\). In contrast, groups 6 and 7 exhibited no obvious differences in the numbers of positive cells compared with that in group 3. Moreover, groups 6 and 7 showed significant decreases in the numbers of positive cells compared with that in group 4 \((P<0.01)\). There were no obvious differences in the number of cells positive for p21, a potent cyclin-dependent kinase (CDK) inhibitor, in groups 3–5. However, the numbers of p21-positive cells were significantly increased in groups 6 and 7 as compared with those in groups 3 \((P<0.01)\) and 4 \((P<0.01)\) versus group 6 and \(P<0.05\) versus group 7).

Multiplying the numbers of cells positive for p53, a well-studied tumor suppressor, were significantly increased in groups 4–7, i.e., all the NMBA-treated groups, compared with that in group 3 \((P<0.01)\). However, there were no obvious immunoreactive differences between group 4 and groups 5–7.

As for all examined markers, the animals in the group 2 exhibited no obvious differences in the immunoreactive cell populations compared with those in group 3.

Table 1. Body Weight, Food Consumption, and Intake of MTBITC

| Group                                | No. of animals | Body weight (g) | Food consumption (g/rat/day) | Intake of MTBITC (mg/kg BW/day) |
|--------------------------------------|----------------|-----------------|-----------------------------|---------------------------------|
|                                      |                | Initial         | Final                       |                                 |
| 1. Untreated                         | 10             | 84.1 ± 6.7      | 364 ± 14.6                  | 15.4                            |
| 2. MTBITC-treated                    | 10             | 84.2 ± 6.5      | 369 ± 28.0                  | 16.3                            |
| 3. DMSO-treated                      | 14             | 84.5 ± 5.4      | 378 ± 14.3                  | 16.5                            |
| 4. NMBA-treated                      | 15             | 84.0 ± 5.4      | 361 ± 21.9                  | 15.8                            |
| 5. NMBA+MTBITC/basal diet            | 15             | 84.0 ± 5.3      | 360 ± 23.3                  | 15.7                            |
| 6. NMBA/MTBITC                       | 15             | 83.9 ± 5.3      | 364 ± 21.4                  | 16.1                            |
| 7. NMBA+MTBITC/MTBITC                | 15             | 83.9 ± 5.2      | 364 ± 27.5                  | 16.7                            |

Body weight values represent the mean ± SD.

Table 2. Incidence and Multiplicity Data for Macroscopic Esophageal Nodules

| Group                                | No. of animals | Incidence (%) | Multiplicity (no./rat) |
|--------------------------------------|----------------|---------------|------------------------|
|                                      |                |               |                        |
| 1. Untreated                         | 10             | 0             |                        |
| 2. MTBITC-treated                    | 10             | 0             |                        |
| 3. DMSO-treated                      | 14             | 0             |                        |
| 4. NMBA-treated                      | 15             | 15 (100)      | 4.53 ± 1.77            |
| 5. NMBA+MTBITC/basal diet            | 15             | 13 (87)       | 1.67 ± 0.98**          |
| 6. NMBA/MTBITC                       | 15             | 12 (80)       | 1.73 ± 1.10**          |
| 7. NMBA+MTBITC/MTBITC                | 15             | 12 (80)       | 1.87 ± 1.19**          |

Multiplicity values represent the mean ± SD. ** \(P<0.01\) versus the NMBA-treated group.

Table 3. Incidence and Multiplicity Data for Esophageal Preneoplastic/Neoplastic Lesions

| Group                                | No. of animals | Incidence (%) | Multiplicity (no./rat) |
|--------------------------------------|----------------|---------------|------------------------|
|                                      |                |               |                        |
| 1. Untreated                         | 10             | 0             |                        |
| 2. MTBITC-treated                    | 10             | 0             |                        |
| 3. DMSO-treated                      | 14             | 0             |                        |
| 4. NMBA-treated                      | 15             | 14 (93)       | 2.73 ± 1.58            |
| 5. NMBA+MTBITC/basal diet            | 15             | 14 (93)       | 1.67 ± 1.23*           |
| 6. NMBA/MTBITC                       | 15             | 14 (93)       | 1.80 ± 1.15            |
| 7. NMBA+MTBITC/MTBITC                | 15             | 14 (93)       | 1.53 ± 1.36*           |

Multiplicity values represent the mean ± SD. * \(P<0.05\) versus the NMBA-treated group. ** \(P<0.01\) versus the NMBA-treated group.
In the present study, we showed that 26 weeks of dietary administration of 80 ppm MTBITC (equivalent to 4.64 mg/kg BW/day) alone did not have any effects in male F344 rats. Importantly, MTBITC treatment clearly inhibited NMBA-induced esophageal carcinogenesis when administered during the initiation and/or promotion phase, causing induction of apoptosis and inhibition of cell proliferation in the promotion phase.

Few in vivo studies have reported the effects of MTBITC on cancer, and the current study is the first report demonstrating the chemopreventive effects of MTBITC on esophageal tumorigenesis in rats. Several other ITCs have also been shown to inhibit carcinogen-induced lung, colonic, pancreatic, and esophageal tumorigenesis, and the characteristics of these ITCs differ, which may contribute to the observed variations in carcinogenesis. For ex-

**Fig. 2.** Representative appearances of esophageal lesions. Normal epithelium (A) in rats in the DMSO-treated group, and squamous cell atypical hyperplasia (B), papilloma (C, D), and carcinoma (E, F) in rats in the NMBA-treated group (HE staining). Atypical hyperplasia exhibits thickening of the squamous epithelium along with the presence of an abnormal cell shape, size, or nuclear morphology, and keratinization of cells within deeper layers of the mucosa is seen. Papilloma is characterized by branching central fibrovascular stalks that are covered by a variably thick and differentiated squamous epithelium that is often heavily keratinized. Cells comprising a carcinoma show features such as loss of polarity (for example, basal-like tumor cells suddenly form keratin pearls), an abundance of mitotic figures, cellular and nuclear pleomorphism, and foci of necrosis. Bars = 100 μm (A, B, D, F) or 1,000 μm (C, E).
ample, unlike dietary administration of 80 ppm MTBITC in the present experiment, 500 ppm of PEITC fails to exert chemopreventive effects on NMBA-induced tumorigenesis in the rat esophagus when administered during the promotion stage\(^1\). In contrast, 80 ppm MTBITC, benzyl isothiocyanate, or sulforaphane (SFN), a type of ITC, prevents BOP-induced pancreatic carcinogenesis in hamsters when administered during the initiation stage but not during the promotion stage\(^1\). These reports, combined with our current findings, indicate that the chemopreventive effects of ITCs may differ depending on the target organ and/or the target molecules of the carcinogen.

In the present study, we also investigated the effects of MTBITC on cell proliferation and apoptosis in the esophageal epithelium of NMBA-treated rats. We found that cleaved caspase-3-positive cells were significantly in-
increased in animals treated with MTBITC during the promotion stage, as compared with that in animals treated with NMBA alone, indicating that MTBITC treatment increased apoptosis. MTBITC has been reported to induce apoptosis in HeLa (human cervical epithelial carcinoma), A549 (human alveolar basal epithelial carcinoma), MCF-7 (human mammary epithelial carcinoma), and PC-3 (human prostate epithelial carcinoma) cell lines\textsuperscript{20}. Specifically, MTBITC was shown to upregulate the expression of Bax and caspase-3, two pro-apoptotic genes, and downregulate the expression of Bcl-2 and Bcl-xl, two anti-apoptotic genes. In terms of cell proliferation, we found that the numbers of Ki-67-positive cells were significantly increased in animals treated with NMBA alone or with MTBITC during the initiation stage as compared with that in animals treated with DMSO. Preneoplastic cells are generally known to have higher proliferative activity than normal cells\textsuperscript{28, 29}, and similar high proliferative activity was previously observed in a rat NMBA carcinogenesis model identical to the model used in this study\textsuperscript{30}. However, the numbers of Ki-67-positive cells were significantly decreased in animals treated with MTBITC during the promotion stage as compared with that in animals treated with NMBA alone, indicating that MTBITC treatment decreased cell proliferation in the esophagus in rats treated with NMBA.

We also investigated the expression of p21 in the rat esophageal epithelium to determine the effects of MTBITC on the cell cycle checkpoint in this model. p21 is a potent CDK inhibitor that blocks cell cycle progression at the G\textsubscript{1}, G\textsubscript{0}, and/or G\textsubscript{0} phase\textsuperscript{31}. In the present study, we found that animals treated with MTBITC during the promotion stage showed higher numbers of p21-positive cells than animals treated with NMBA alone. Several studies have shown that ITCs upregulate the expression of p21 and suppress the expression of cyclins and CDKs, resulting in induction of cell cycle arrest by PEITC in MCF-7 and MDA-MB-231 cells (derived from human breast adenocarcinomas) and by SFN in LNCaP and PC-3 cells (derived from human prostate adenocarcinomas)\textsuperscript{2, 3}. SFN has been known to induce apoptosis derived from reactive oxygen species\textsuperscript{32} and to elevate the transcription of p21 through the inhibition of histone deacetylase (HDAC) activity\textsuperscript{33} in human prostate adenocarcinoma cells. Furthermore, MTBITC shares a similar chemical structure with SFN; therefore, MTBITC might have similar activity regarding ROS induction and HDAC inhibition. Further investigation is needed to clarify this. Consequently, our results suggest that MTBITC treatment may suppress cell proliferation through increased expression of p21, at least in part, in the rat esophageal epithelium.

Interestingly, rats in all NMBA-treated groups showed increased numbers of p53-positive cells in the esophagus compared with that in the DMSO-treated group, regardless of the presence of MTBITC treatment. p53 is a short-lived protein in normal tissues; however, mutant p53 protein has an extended half-life and is often highly expressed in tumor cells\textsuperscript{35}. Mutations in the p53 gene have been observed in NMBA-induced esophageal tumors in rats\textsuperscript{36} and in esophageal tumors in humans\textsuperscript{37}. Thus, the increased number of p53-positive cells may be explained by NMBA treatment, and MTBITC may not have affected the expression of p53 in the esophagus of NMBA-treated rats. However, we did not investigate mutations in the p53 gene directly in our study.

Compared with the esophagus in the vehicle control group, administration of MTBITC alone did not alter these factors on the esophageal epithelium, suggesting that MTBITC may have selectively affected the NMBA-treated esophageal cells, while the normal esophageal cells were left unaffected. Selective targeting and negligible toxicity in normal cells are important prerequisites for probable chemopreventive compounds. Similarly, ITCs, including MTBITC, have been reported to induce cell cycle arrest and apoptosis in preneoplastic/neoplastic cells but not in normal cells, for example, higher cell proliferative activity\textsuperscript{28, 29}.

MTBITC has been shown to inhibit genotoxicity \textit{in vitro} and \textit{in vivo}\textsuperscript{2, 3} and to induce several types of antioxidative enzymes, including quinone reductase, NAD(P)H:quinone oxidoreductase, heme oxygenase-1, thioredoxin reductase, and glutathione S-transferase in HepG2 (human hepatocellular carcinoma) cells or hepatocytes of rats and mice\textsuperscript{21, 22}. Moreover, induction of antioxidative enzymes is transcriptionally regulated through the antioxidant response element (ARE), and activation of gene transcription through the ARE is mediated primarily by nuclear factor E2-related factor 2 (Nrf2)\textsuperscript{38}. Indeed, several types of ITCs, including MTBITC, activate Nrf2 in primary cultures of rat hepatocytes\textsuperscript{21}. Furthermore, several ITCs have been reported to inhibit the induction of cytochrome P450 (CYP) enzymes. CYP enzymes are generally known to activate certain carcinogens, and simultaneous administration of PEITC has been reported to inhibit NMBA-induced esophageal carcinogenesis in rats through its ability to reduce the metabolism of NMBA and to inhibit the DNA adduct formation induced by NMBA metabolites\textsuperscript{43}. PEITC also inhibits CYP1A2, CYP2E1, and CYP3A4 in rat liver microsomes\textsuperscript{39}. In addition, MTBITC inhibits CYP3A2 in primary cultures of rat hepatocytes\textsuperscript{21}. Based on these reports, MTBITC treatment during the initiation phase may affect the Nrf2-ARE pathway and the inhibition of CYP enzymes in the rat esophagus. Further studies are needed to confirm this hypothesis.

In conclusion, we showed for the first time that treatment with approximately 4–6 mg MTBITC/kg BW/day suppressed NMBA-induced esophageal tumorigenesis when administered during the initiation and/or promotion stages. Converting this dose based on body surface area as described in the FDA guidance\textsuperscript{40}, the human equivalent dose would be 0.65–0.98 mg/kg BW/day. The above effects were related to the induction of apoptosis and the suppression of cell proliferation in NMBA-treated esophageal cells with elevated p21 expression. On the other hand, these changes were not observed in the animals treated with MTBITC alone, suggesting the specificity of MTBITC to NMBA-
initiated cells but not to the normal esophageal epithelium. Based on the previously reported concentration of MTBITC in heirloom daikon varieties such as Karami, Momoyama, and Sabaga (421, 276, 227 μmol/100 g, respectively)⁹, the estimated daily dose of MTBITC in this study was equal to about 60–160 g heirloom daikon in humans (60 kg BW); therefore, it is feasible to consume a sufficient amount of heirloom daikon containing MTBITC to achieve chemoprevention for esophageal cancer. Further studies of the efficacy of MTBITC will provide additional insights into the health benefits of daikon.

Acknowledgments: The authors thank Ayako Saikawa and Yoshimi Komatsu for their technical assistance in preparing the histological specimens. This work was supported by Japan Society for the Promotion of Science KAKENHI (Grant-in-Aid for Challenging Exploratory Research) Grant Number 25560039, the Kyoto Prefectural Agriculture, Forestry and Fisheries Technology Center, and the Committee for the Promotion of Kyoto Vegetables as Functional Foods.

Disclosure of Potential Conflicts of Interest: Isamu Suzuki is an employee of BoZo Research Center Inc., Shizuoka, Japan, and Tadashi Hirata is an employee of Japan Tobacco Inc., Kanagawa, Japan. The authors declare that they have no conflicts of interest.

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, and Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. 2013, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

2. Enzinger PC, and Mayer RJ. Esophageal cancer. N Engl J Med. 349: 2241–2252. 2003. [Medline] [CrossRef]

3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 59: 225–249. 2009. [Medline] [CrossRef]

4. Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, Nakayama M, Matsuoka M, Hattori M, Sugiyama H, Oze I, Tanaka R, Nomura E, Nishino Y, Matsuda T, Ioka A, Tsukuma H, Nakayama T. J-CANSIS Research Group Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 105: 1480–1486. 2014. [Medline] [CrossRef]

5. Kamangar F, Chow WH, Abnet CC, and Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 38: 27–57. vii. 2009. [Medline] [CrossRef]

6. Zhang N, Yu C, Wen D, Chen J, Ling Y, Terajima K, Akazawa K, Shan B, and Wang S. Association of nitrogen compounds in drinking water with incidence of esophageal squamous cell carcinoma in Shexian, China. Tohoku J Exp Med. 226: 11–17. 2012. [Medline] [CrossRef]

7. Freedman ND, Park Y, Subar AF, Hollembekk AR, Leitzmann MF, Schatzkin A, and Abnet CC. Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer. 121: 2753–2760. 2007. [Medline] [CrossRef]

8. Yamaji T, Inoue M, Sasazuki S, Iwasaki M, Kurahashi N, Shimazu T, and Tsugane S. Japan Public Health Center-based Prospective Study Group Fruit and vegetable consumption and squamous cell carcinoma of the esophagus in Japan: the JPHC study. Int J Cancer. 123: 1935–1940. 2008. [Medline] [CrossRef]

9. IARC Cruciferous Vegetables, Isothiocyanates and Indoles. IARC Handbooks of Cancer Prevention, Vol. 9. Lyon. 2004.

10. Chung FL, Conaway CC, Rao CV, and Reddy BS. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis. 21: 2287–2291. 2000. [Medline] [CrossRef]

11. Yang YM, Conaway CC, Chiao JW, Wang CX, Amin S, Whyens J, Dai W, Reinhardt J, and Chung FL. Inhibition of benzo(a)pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcycteine conjugates of benzyl and phenethy l isothiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res. 62: 2–7. 2002. [Medline]

12. Nishikawa A, Furukawa F, Kasahara K, Tanakamaru M, Miyachi M, Nakamura H, Ikeda T, Imazawa T, and Hirose M. Failure of phenethyl isothiocyanate to inhibit hamster tumorigenesis induced by N-nitrosobis(2-oxopropyl)amine when given during the post-initiation phase. Cancer Lett. 141: 109–115. 1999. [Medline] [CrossRef]

13. Kuroiwa Y, Nishikawa A, Kitamura Y, Kanki K, Ishii Y, Umemura T, and Hirose M. Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Lett. 245: 275–280. 2006. [Medline] [CrossRef]

14. Siglit JC, Barch DH, and Stoner GD. Effects of dietary phenethyl isothiocyanate, ellagic acid, sulindac and calcium on the induction and progression of N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Carcinogenesis. 16: 1101–1106. 1995. [Medline] [CrossRef]

15. Stoner GD, Morrissey DT, Heur YH, Daniel EM, Galati AJ, and Wagner SA. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res. 51: 2063–2068. 1991. [Medline]

16. Stoner GD, and Gupta A. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis. 22: 1737–1746. 2001. [Medline] [CrossRef]

17. Nakamura Y, Iwashashi T, Tanaka A, Koutani J, Matsuo T, Okamoto S, Sato K, and Ohtsuki K. 4-(Methylthio)-3-butenyl isothiocyanate, a principal antimutagen in daikon (Raphanus sativus; Japanese white radish). J Agric Food Chem. 49: 5755–5760. 2001. [Medline] [CrossRef]

18. Okamura T, Umemura T, Inoue T, Tasaki M, Ishii Y, Nakamura Y, Park EY, Sato K, Matsu T, Okamoto S, Nishikawa A, and Ogawa K. Chemopreventive effects of 4-methylthio-3-butenyl isothiocyanate (Raphasatin) but not curcumin against pancreatic carcinogenesis in hamsters. J Agric Food Chem. 61: 2103–2108. 2013. [Medline] [CrossRef]

19. Nakamura Y, Nakamura K, Asai Y, Wada T, Tanaka K, Matsu T, Okamoto S, Meijer J, Kitamura Y, Nishikawa A, Park EY, Sato K, and Ohtsuki K. Comparison of the glucosinolate-myrosinase systems among daikon (Raphanus sativus; Japanese white radish) varieties. J Agric Food Chem. 56: 2702–2707. 2008. [Medline] [CrossRef]

20. Beevi SS, Mangamoori LN, Subathra M, and Edula JR. [CrossRef]
Hexane extract of *Raphanus sativus* L. roots inhibits cell proliferation and induces apoptosis in human cancer cells by modulating genes related to apoptotic pathway. Plant Foods Hum Nutr. 65: 200–209. 2010. [Medline] [CrossRef]

21. La Marca M, Beffy P, Della Croce C, Gervasi PG, Iori R, Puccinelli E, and Longo V. Structural influence of isothiocyanates on expression of cytochrome P450, phase II enzymes, and activation of Nrf2 in primary rat hepatocytes. Food Chem Toxicol. 50: 2822–2830. 2012. [Medline] [CrossRef]

22. Scholl C, Eshelman BD, Barnes DM, and Hanlon PR. Raphasatin is a more potent inducer of the detoxification enzymes than its degradation products. J Food Sci. 76: C504–C511. 2011. [Medline] [CrossRef]

23. Ben Salah-Abbès J, Abbès S, Ouanes Z, Abdel-Wahhab MA, Bacha H, and Oueslati R. Isothiocyanate from the Tunisian radish (*Raphanus sativus*) prevents genotoxicity of Zearalenone in *vivo* and *in vitro*. Mutat Res. 677: 59–65. 2009. [Medline] [CrossRef]

24. Lu SH, Chui SX, Yang WX, Hu XN, Guo LP, and Li FM. Relevance of *N*-nitrosamines to oesophageal cancer in China. IARC Sci Publ. 105: 11–17. 1991. [Medline]

25. Nolte T, Brander-Weber P, Dangler C, Deschl U, Elwell MR, Greaves P, Hailey R, Leach MW, Pandiri AR, Rogers A, Shackelford CC, Spencer A, Tanaka T, and Ward JM. Nonproliferative and proliferative lesions of the gastrointestinal tract, pancreas and salivary glands of the rat and mouse. J Toxicol Pathol. 29(Suppl): 1S–125S. 2016. [Medline] [CrossRef]

26. Tanai E, Yafune A, Kimura M, Morita R, Nakane F, Suzuki K, Mitsumori K, and Shibutani M. Fluctuations in *p53* expression of normal and neoplastic tissue growth. Toxicol Pathol. 37(Suppl): 1982s–1986s. 1994. [Medline] [CrossRef]

27. Akagi K, Sano M, Ogawa K, Hirose M, Goshima H, and Shirai T. Involvement of toxicity as an early event in urinary bladder carcinogenesis induced by phenethyl isothiocyanate, benzyl isothiocyanate, and analogues in F344 rats. Toxicol Pathol. 31: 388–396. 2003. [Medline] [CrossRef]

28. Foster JR. Cell death and cell death in the control of normal and neoplastic tissue growth. Toxicol Pathol. 28: 441–446. 2000. [Medline] [CrossRef]

29. Ogawa K. Molecular pathology of early stage chemically induced hepatocarcinogenesis. Pathol Int. 59: 605–622. 2009. [Medline] [CrossRef]

30. Lechner JF, Wang LS, Rocha CM, Larue B, Henry C, McIntyre CM, Riedl KM, Schwartz SJ, and Stoner GD. Drinking water with red beetroot food color antagonizes esophageal carcinogenesis in *N*-nitrosomethylbenzylamine-treated rats. J Med Food. 13: 733–739. 2010. [Medline] [CrossRef]

31. Dutto I, Tillhön M, Cazzalini O, Stivala LA, and Prosperi E. Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology. Arch Toxicol. 89: 155–178. 2015. [Medline] [CrossRef]

32. Sarkars R, Mukherjee S, and Roy M. Targeting heat shock proteins by phenethyl isothiocyanate results in cell-cycle arrest and apoptosis of human breast cancer cells. Nutr Cancer. 65: 480–493. 2013. [Medline] [CrossRef]

33. Clarke JD, Hsu A, Yu Z, Dashwood RH, and Ho E. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol Nutr Food Res. 55: 999–1009. 2011. [Medline] [CrossRef]

34. Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, Lee YJ, Xiao H, and Herman-Antosiewicz A. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem. 280: 19911–19924. 2005. [Medline] [CrossRef]

35. Evke E, Minbay FZ, Temel SG, and Kahveci Z. Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. J Mol Histol. 40: 13–21. 2009. [Medline] [CrossRef]

36. Wang D, Weghorst CM, Calvert RJ, and Stoner GD. Mutation in the *p53* tumor suppressor gene in rat esophageal papillomas induced by *N*-nitrosomethylbenzylamine. Carcinogenesis. 17: 625–630. 1996. [Medline] [CrossRef]

37. Greenblatt MS, Bennett WP, Hollstein M, and Harris CC. Mutations in the *p53* tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855–4878. 1994. [Medline]

38. Nguyen T, Nioi P, and Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 284: 13291–13295. 2009. [Medline] [CrossRef]

39. Yang CS, Smith TJ, and Hong JY. Cytochrome P-450 enzymes as targets for chemoprevention against chemical carcinogenesis and toxicity: opportunities and limitations. Cancer Res. 54(Suppl): 1982s–1986s. 1994. [Medline]

40. FDA Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for industry, Rockville. 2005. http://www.fda.gov/downloads/Drugs/guidancecomplianceregulatoryinformation/Guidances/UCM078932.pdf.